The Canadian government has granted Optimi Health Corp., a startup, the approval to export medical substances derived from psychedelic plants to Australia. These substances include psilocybin, extracted from magic mushrooms, and MDMA, both sanctioned by the health department.
Demand is not only growing locally, as seen in the magic mushrooms Ontario market, but other countries are also following Canada’s lead. They are investigating and approving the use of serotogenic compounds for therapeutic applications.
You can purchase psychedelics online in Canada with confidence, tapping into your innate potential through trustworthy sources.
[toc]Key Points:
- Vancouver-based startup Optimi Health has received a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment consists of three sessions, each lasting about eight hours, spread over five to eight weeks.
The Rise of Psilocybin Capsules in Canada
Vancouver-based Optimi Health is aiming to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain a foothold early on.
Seven companies have exported psilocybin, MDMA, or both, but only for clinical trials. A spokesperson from Canada’s health department could not confirm if these exports were for regular patient use and chose not to reveal the companies’ names due to safety reasons.
This milestone places Optimi among a limited number of international suppliers, as the current market is more focused on clinical rather than recreational use.
What Does the Pill Contain?
The company has not disclosed the specific type of mushroom used in the pill, however they work with a range of strains including Albino Penis Envy, among others.
A 20,000-square-foot facility in Princeton, British Columbia, has been established by Optimi to cultivate, examine, and extract its psychedelic mushrooms. This quaint town, home to around 3,000 inhabitants, is situated a three-hour drive east of Vancouver.
Australia and Psychedelic Mushrooms: A Complex Relationship
It’s projected that one in five Australians aged 16-85 may grapple with a mental illness. PTSD (post-traumatic stress disorder) might affect 11% of Australians at some point in their life, while anxiety disorders are common in 17% of the populace.
Though there is a broad spectrum of treatments for mental disorders, not all are efficacious for every person. Those who do not respond to certain therapies might find it difficult to identify a method that is helpful, thereby heightening their susceptibility.
The Procedure Explained
Australia has been at the forefront of integrating psilocybin into treatment, allowing licensed psychiatrists to use this regulated substance in the treatment of PTSD and treatment-resistant depression.
In a groundbreaking decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic purposes. The TGA stated that these substances are secure when used in a medically supervised environment for patients with severe mental disorders.
This step has marked a turning point for many mental health professionals and researchers. The employment of these substances will be strictly monitored; it’s not as simple as taking a pill and departing.
The treatment protocol typically comprises three sessions spanning five to eight weeks. Each session endures about eight hours, with the therapist staying with the patient throughout.
Canada’s Role in Psilocybin Research
Canada has emerged as a leading center for research into psilocybin, substantially expanding our understanding of this compound. Health Canada, in collaboration with multiple institutions, is spearheading the investigation into psilocybin’s therapeutic potential for various mental health disorders.
Research bodies no longer need to classify these substances as illegal or rely on unregulated dispensaries or mushroom stores. The government now permits certain institutions to grow mushrooms for research purposes.
The increased accessibility to substances previously deemed harmful enables researchers to deepen their understanding of their potential benefits for many individuals.
A Recurring Trends
The potential of this domain was initially recognized in the 1950s as a solution for mental health problems and substance addictions, including alcohol abuse. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were key leaders in this early research conducted at the Saskatchewan Mental Hospital in Weyburn. The hospital saw significant progress under the leadership of the then-premier Tommy Douglas, who granted considerable autonomy to the medical community for exploring their theories.
Dr. Osmond and Dr. Hoffer initiated research into the use of LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research expanded in unexpected ways, with the pair advocating for medical professionals and support staff to test these substances.
Research at Canadian Health Institutes
Under the umbrella of the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials. These trials aim to investigate the therapeutic efficiency and safety of psilocybin-assisted psychotherapy as follows:
| Project Type | Study Focus | Research Establishment | Lead Researcher | Project Budget |
| A randomized controlled trial | Psychological distress in end-of-life advanced-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Psychotherapy mechanisms support for psilocybin in treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research sponsorship will contribute to a deeper understanding of the potential benefits of controlled substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada, has made this funding possible.
Further Psychedelic Research
Vancouver psychiatrists have begun a phase III clinical trial of MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder (PTSD). The treatment involves three eight-hour MDMA sessions, spaced one month apart, and nine 90-minute sessions without the drug. This trial is considered historically significant as it marks the first clinical exploration of an illegal
This is the first new legal psychedelic substance in more than four decades.
Getting to Know Psilocybin
Psilocybin is a naturally present psychedelic compound in certain types of mushrooms. Upon ingestion, it is metabolized into psilocin which then activates the serotonin 5-HT2a receptors found in the cortical pyramidal cells of the brain, the principal processing centers.
The substance is currently under investigation by local authorities for its potential to help with depression, anxiety, addiction, and end-of-life distress through encouraging introspection and spiritual enlightenment.
Why is it Potentially Effective Against Depression, PTSD, and More?
The active ingredient affects various regions of the brain, making it potentially beneficial for a range of mental disorders. Many patients in Canada and Australia have already been treated using this therapy, and the reported results are promising, with minor side effects like temporary anxiety or increased blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound acts as a partial agonist at serotonin receptors, primarily the 5-HT2A subtype, which plays a crucial role in emotional processing and mood regulation.
- Default Mode Network (DMN) Modulation: It reduces activity in the DMN, promoting introspection, decreasing rigid thought patterns, and encouraging emotional flexibility.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the substance are a result of its influence on the prefrontal and limbic areas of the brain, including the amygdala. In cases of depression, people often show reduced responsiveness to emotional triggers. This compound boosts the response to positive emotional triggers in the right amygdala and diminishes or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Generation of Positive Mood States: It promotes feelings of euphoria, interconnectedness, and emotional openness during and following the experience.
- Enhanced Emotional Processing: The psychedelic journey may allow individuals to confront and process deeply embedded emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research conducted by Johns Hopkins University and Imperial College Studies out of London suggest that magic mushrooms can instigate enduring positive changes, encompassing enhanced well-being, a boost in life satisfaction, and spiritual growth.
What Can You Discover in Your Local Magic Mushroom Store?
If you are intrigued about how these substances could impact your mental health, explore your local magic mushroom store to find a product that aligns with your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, ignites creative thinking, and heightens productivity and concentration |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and enhances overall life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Enhances clarity, creativity, and focus. Contains a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
Worldwide Acceptance of Psilocybin
Canada is not the sole country advocating the use of magic mushrooms for mental health challenges. Countries like Australia are also embracing these psychedelic substances to address issues such as depression and PTSD. They procure top-grade psychedelic capsules from trusted sources. Under suitable supervision, patients can significantly improve their life quality. Shroom Delivery Canada, a magic mushroom supplier, offers a wide array of products, ranging from capsules to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Psilocybin and MDMA share therapeutic potentials by boosting mental health. Psilocybin interacts with serotonin 2A receptors, making it useful for treating depression and addiction.
Conversely, MDMA engenders empathy and is beneficial in PTSD treatment. It exhibits potential in improving emotional processing and
Despite being classified as a controlled substance, the treatment has shown promising therapeutic results.
Is this treatment accessible to all Australians?
No, it is not. In Australia, individuals are required to undergo a suitability evaluation before they can use the substance. This assessment takes into account factors such as existing heart conditions and past instances of psychosis, among others. The treatment is only accessible to patients who have not found relief from traditional treatments for conditions like depression, anxiety, or PTSD.
What would be the implications of Canada exporting mushrooms?
Canada is setting itself up to be a major player in the psychedelics market, much like it did with cannabis. This move could prompt more companies to produce high-quality products. As a result, Canada could become a market leader in the hallucinogen industry, strengthen its economy, and enable other countries to access these treatments. It would also prevent other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thus ensuring safety.
Articles You Might Find Intriguing:
